The Quantification of Oxycodone and Its Phase I and II Metabolites in Urine.


Journal

Journal of analytical toxicology
ISSN: 1945-2403
Titre abrégé: J Anal Toxicol
Pays: England
ID NLM: 7705085

Informations de publication

Date de publication:
14 Feb 2022
Historique:
received: 20 10 2020
revised: 26 11 2020
accepted: 02 12 2020
pubmed: 4 12 2020
medline: 16 2 2022
entrez: 3 12 2020
Statut: ppublish

Résumé

The purpose of this research was to develop and validate an analytical method for the detection and quantification of noroxymorphone-3β-D-glucuronide (NOMG), oxymorphone-3β-D-glucuronide (NOMG), noroxymorphone (NOM), oxymorphone (OM), 6α-oxycodol (αOCL), 6β-oxycodol (βOCL), noroxycodone (NOC) and oxycodone (OC) in urine by liquid chromatography tandem mass spectrometry to be used in a human study. The method was validated according to the Academy Standards Board Standard Practices for Method Development in Forensic Toxicology. The method was then applied to a single-dose pilot study of a subject. Urine samples were collected from the subject after ingesting 10-mg OC as an immediate-release tablet. Additionally, urine specimens (n = 15) that had previously been confirmed positive for OC were analyzed using the validated method. The calibration range for NOMG and OMG was 0.05-10 μg/mL; for all other analytes, it was 0.015-10 μg/mL. Validation parameters such as bias, precision, carryover and dilution integrity, all met the validation criteria. After the method was validated, urine samples from the first subject in the controlled dose study were analyzed. It was observed that OC, NOC and OMG contained the highest concentrations and were present in either the 0.5 or 1 h void. NOC and OMG were detected until the 48 h collection, while OC was detectable till the 24 h collection. Time to reach maximum concentration (Tmax) in the urine was achieved within 1.5 h for OC and within 3 h for NOC and OMG. Maximum concentration (Cmax) in the urine for OC, NOC and OMG was 3.15, 2.0 and 1.56 μg/mg, respectively. OC concentrations in authentic urines ranged from 0.015 to 12 μg/mL. Ranges for NOMG and OMG were 0.054-9.7 μg/mL and 0.14-67 μg/mL, respectively. A comprehensive method for the quantification of NOMG, OMG, NOM, OM, αOCL, βOCL, NOC and OC in urine was optimized and met the validation criteria. The concentrations of NOMG and OMG presented in this study provide the details needed in the forensic community to better comprehend OC pharmacokinetics.

Identifiants

pubmed: 33270113
pii: 6017808
doi: 10.1093/jat/bkaa186
pmc: PMC8841981
doi:

Substances chimiques

Oxymorphone 9VXA968E0C
Oxycodone CD35PMG570

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

55-63

Subventions

Organisme : Strategic research area in forensic sciences at the University of Linköping
ID : Grant projects 304399 and 304774

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press.

Références

J Pharm Anal. 2018 Jun;8(3):160-167
pubmed: 29922484
Br J Clin Pharmacol. 1992 Jun;33(6):617-21
pubmed: 1389934
J Anal Toxicol. 2018 Mar 1;42(2):115-125
pubmed: 29186453
Scand J Pain. 2019 Apr 24;19(2):345-353
pubmed: 30677000
J Anal Toxicol. 2013 Jul-Aug;37(6):337-44
pubmed: 23743505
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:174-180
pubmed: 26655109
J Pharm Biomed Anal. 2018 Apr 15;152:204-214
pubmed: 29414014
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):264-70
pubmed: 17098487
J Anal Toxicol. 2010 Jan-Feb;34(1):32-8
pubmed: 20109300
Subst Use Misuse. 2018 Jul 3;53(8):1288-1298
pubmed: 29293038
J Mass Spectrom. 2006 May;41(5):633-40
pubmed: 16541404
J Anal Toxicol. 2007 Jan-Feb;31(1):1-14
pubmed: 17389078
J Chromatogr A. 2004 Oct 8;1051(1-2):273-82
pubmed: 15532584
J Anal Toxicol. 2013 Jun;37(5):255-64
pubmed: 23609023
Clin Chem Lab Med. 2017 Aug 28;55(9):1324-1331
pubmed: 28080998
J Anal Toxicol. 2012 Oct;36(8):541-7
pubmed: 22833646
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 1;878(7-8):637-44
pubmed: 20138595
Ther Drug Monit. 2008 Jun;30(3):333-40
pubmed: 18520605
J Chromatogr Sci. 2002 Jan;40(1):40-4
pubmed: 11866386
J Anal Toxicol. 2003 Sep;27(6):346-52
pubmed: 14516487

Auteurs

Michael T Truver (MT)

Division of Drug Research, Department of Biomedical and Clinical Sciences, Faculty of Medicine, Linköping University, Linköping 581 83, Sweden.

Gerd Jakobsson (G)

Division of Drug Research, Department of Biomedical and Clinical Sciences, Faculty of Medicine, Linköping University, Linköping 581 83, Sweden.
Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping 587 58, Sweden.

Maria D Chermà (MD)

Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping 587 58, Sweden.

Madeleine J Swortwood (MJ)

Department of Forensic Science, College of Criminal Justice, Sam Houston State University, 1003 Bowers Blvd, Huntsville, TX, USA.

Henrik Gréen (H)

Division of Drug Research, Department of Biomedical and Clinical Sciences, Faculty of Medicine, Linköping University, Linköping 581 83, Sweden.
Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping 587 58, Sweden.

Robert Kronstrand (R)

Division of Drug Research, Department of Biomedical and Clinical Sciences, Faculty of Medicine, Linköping University, Linköping 581 83, Sweden.
Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping 587 58, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH